QPPV.COM KNOWLEDGE ASSESSMENT

Ocrelizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Ocrelizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why can ocrelizumab deplete relevant B-cell populations while allowing some immune recovery over time?

CD20 is expressed on stem cells, but the antibody effect is rapidly neutralised by plasma cells CD20-positive cells are depleted, while stem cells and early precursors lacking CD20 remain available for later B-cell reconstitution The antibody only binds B cells during a brief infusion window and has no prolonged biological effect Ocrelizumab converts mature B cells into plasma cells rather than depleting them

Question 2 of 10 A patient develops localized erythema and swelling after subcutaneous ocrelizumab, without respiratory or cardiovascular symptoms. How should the initial case assessment classify the reaction?

As a definite systemic hypersensitivity reaction As a local injection-site manifestation, while assessing separately for systemic features As an intravenous infusion reaction because the active antibody is the same As evidence of hepatitis B reactivation

Question 3 of 10 Why does maternal ocrelizumab exposure require pharmacovigilance follow-up beyond the date of delivery?

The antibody cannot cross the placenta, so only maternal outcomes matter Placental transfer, particularly later in pregnancy, can result in transient neonatal B-cell depletion with implications for immune monitoring and vaccination Infant outcomes are unrelated to the timing of maternal doses Neonatal B-cell counts are relevant only when the mother had an infusion reaction

Question 4 of 10 Which additional information would be most valuable when assessing a serious respiratory infection in an ocrelizumab-treated patient?

Only the pathogen name, without treatment or immune data The patient's eye colour and the date of MS diagnosis Infection site and organism, hospital course, immunoglobulin values, prior immunosuppression and relevant disability-related risk factors Only whether the patient received premedication before the last dose

Question 5 of 10 Which data-field design would best support route-specific pharmacovigilance for ocrelizumab?

One generic field labelled 'administration reaction' with no route or product details Separate fields for intravenous versus subcutaneous presentation, local versus systemic features, dose number, onset, rate and management A field recording only the patient's preferred route A product field that excludes batch and preparation information

Question 6 of 10 A patient receiving ocrelizumab develops persistent diarrhoea. Which pharmacovigilance approach is most consistent with the article?

Assume infection and close the case if initial cultures are negative Assume the symptom is unrelated to ocrelizumab because the product is long established Evaluate infection and other causes while considering immune-mediated colitis and obtaining appropriate investigations such as stool studies and, where indicated, endoscopy Classify the event as an infusion reaction regardless of its timing

Question 7 of 10 Which inspection finding would most strongly indicate that an organisation's immunoglobulin-monitoring control is ineffective?

The procedure requests immunoglobulin results before treatment The organisation has a route-specific product dictionary Repeated serious or recurrent infection cases routinely lack baseline and serial immunoglobulin values despite the procedure requiring them The organisation documents whether cases involve relapsing or primary progressive MS

Question 8 of 10 Which finding is necessary before a hepatic event should be labelled as hepatitis B reactivation?

A history of any infection during ocrelizumab treatment Elevated liver enzymes alone Virological evidence such as renewed or increased HBV DNA, interpreted with pretreatment serology and clinical data The presence of fatigue and nausea alone

Question 9 of 10 Which product-identification practice is most important when evaluating a suspected administration error involving ocrelizumab?

Record only the antibody's international nonproprietary name Record the patient's MS phenotype but not the administration route Distinguish the intravenous product from the hyaluronidase-containing subcutaneous presentation and document route and batch Treat all ocrelizumab products as interchangeable for pharmacovigilance purposes

Question 10 of 10 Which pattern provides the strongest pharmacovigilance signal for clinically meaningful hypogammaglobulinaemia?

A single low immunoglobulin measurement without clinical context Progressive immunoglobulin decline accompanied by recurrent or serious infections over repeated treatment cycles A normal immunoglobulin value measured before the first dose A transient local injection-site reaction

Ocrelizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings